Calls
2
Rebecca Liang
Reporter, The Block
Win Rate
50.0%
return
+1.7%
Loading charts...
Ticker
Side
Mentions
First Call
Call Price
P&L
Thesis
Theme
Source
Long
Apr 27
$84.10
+7.0%
She recommends Innovent Biologics and Hengrui Medicine as top picks in the Chinese pharmaceutical sector. Innovent is a maturing biopharma transitioning to global level with a strong pipeline and deal-making capability. Hengrui is a traditional company successfully phasing out legacy products and replenishing with innovative drugs. Both have clinical catalysts and are positioned to benefit from China's growing dominance in global drug R&D.
Pharma & Biotech
Long
Apr 27
$55.38
-3.5%
She recommends Innovent Biologics and Hengrui Medicine as top picks in the Chinese pharmaceutical sector. Innovent is a maturing biopharma transitioning to global level with a strong pipeline and deal-making capability. Hengrui is a traditional company successfully phasing out legacy products and replenishing with innovative drugs. Both have clinical catalysts and are positioned to benefit from China's growing dominance in global drug R&D.
Pharma & Biotech
Showing 2 of 2 calls · sorted by mentions
Choose a mentions count to open ticker posts.
Rebecca Liang has 2 trade ideas tracked on Buzzberg across 2 tickers since April 2026. Most covered: 1801.HK, 600276.SS.
